Climb Bio, Inc. (CLYM) stock
CLYMNasdaqPharmaceutical PreparationsFiscal year ends December 31
$9.78−0.16 (-1.61%)
Close on Nov 17, 2026Market cap $561.73MP/E –Yield –
Climb Bio cash
Cash and short-term investments held at the end of each period.
Climb Bio's cash was $183.12M at Jun 30, 2026. For fiscal 2025 it was $160.70M, up 6.5% from the year before. The highest annual figure on record is $161.40M in fiscal 2021.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $160.70M | +6.5% |
| FY2024 | Dec 31, 2024 | $150.92M | +41.3% |
| FY2023 | Dec 31, 2023 | $106.80M | -13.6% |
| FY2022 | Dec 31, 2022 | $123.60M | -23.4% |
| FY2021 | Dec 31, 2021 | $161.40M | +687.8% |
| FY2020 | Dec 31, 2020 | $20.49M | -3.5% |
| FY2019 | Dec 31, 2019 | $21.22M | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $183.12M | +116.2% |
| Q1 FY2026 | Mar 31, 2026 | $109.56M | +11.7% |
| Q4 FY2025 | Dec 31, 2025 | $160.70M | +6.5% |
| Q3 FY2025 | Sep 30, 2025 | $86.90M | -55.1% |
| Q2 FY2025 | Jun 30, 2025 | $84.70M | -62.0% |
| Q1 FY2025 | Mar 31, 2025 | $98.06M | -6.6% |
| Q4 FY2024 | Dec 31, 2024 | $150.92M | +41.3% |
| Q3 FY2024 | Sep 30, 2024 | $193.35M | +80.0% |
| Q2 FY2024 | Jun 30, 2024 | $223.14M | +117.4% |
| Q1 FY2024 | Mar 31, 2024 | $105.03M | -4.0% |
| Q4 FY2023 | Dec 31, 2023 | $106.80M | -13.6% |
| Q3 FY2023 | Sep 30, 2023 | $107.43M | -12.4% |
| Q2 FY2023 | Jun 30, 2023 | $102.63M | -16.5% |
| Q1 FY2023 | Mar 31, 2023 | $109.37M | -27.0% |
| Q4 FY2022 | Dec 31, 2022 | $123.60M | -23.4% |
| Q3 FY2022 | Sep 30, 2022 | $122.62M | -16.0% |
| Q2 FY2022 | Jun 30, 2022 | $122.95M | +23.6% |
| Q1 FY2022 | Mar 31, 2022 | $149.90M | +212.9% |
| Q4 FY2021 | Dec 31, 2021 | $161.40M | +687.8% |
| Q3 FY2021 | Sep 30, 2021 | $146.02M | +1050.7% |
| Q2 FY2021 | Jun 30, 2021 | $99.48M | +552.8% |
| Q1 FY2021 | Mar 31, 2021 | $47.91M | +125.8% |
| Q4 FY2020 | Dec 31, 2020 | $20.49M | – |
| Q3 FY2020 | Sep 30, 2020 | $12.69M | – |
| Q2 FY2020 | Jun 30, 2020 | $15.24M | – |
| Q4 FY2019 | Dec 31, 2019 | $21.22M | – |
See a number that looks wrong?